Bottom line - It seems quite evident that for IPIX to succeed and our drugs have any chance of seeing the light of day that we will be required to have a "favored" partner by the medical/government establishment. Another way of saying "greasing the right palms" IMO. If Leo hasn't figured this out yet maybe time to get rid of him. He has suffered nothing with his pay still quite robust (and has been all these last 10 years or so) and his "need for speed" is lacking IMO
The green shoots of reality are poking through the ground.
The lack of a substantial partner over the last seven years indicates that either the drugs are worthless or the CEO is worthless.
People are starting to do the math. There is enough cash in the chest to pay back Leo's loan to the company and I suspect it will remain that way until the end. In the meantime he collects ~$500K/year to fail at delivering shareholder value. It's a great gig if you can get it.
Leo has lots of shares but no skin in the game so long as that cash balance stays above $5M. It's just a day job for him. He basically writes his own performance reviews as well.
I'm holding out hope for some deal making capitulation to make back a little coin but it probably won't be pretty. Still $0.15 or $0.25 would be a lot better than $0.05.